Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,954 DKK | +2.04% | -2.57% | -9.30% |
Apr. 16 | Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug | MT |
Apr. 16 | Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.30% | 18.15B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B | |
-24.71% | 8.24B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Genmab A/S : RBC Capital Adjusts Genmab A/S' Price Target to $40 From $38, Maintains Outperform Rating